WEBULL
WebtradeDownload

Why Clorox (CLX) Is Up 6.2% After GOJO-Driven 2027 Outlook And Dividend Hike

Simply Wall St · 2d ago
  • The Clorox Company recently reported that full-year 2026 sales fell to US$6,720 million and net income to US$587 million, while also issuing fiscal 2027 guidance calling for higher net sales and diluted EPS, and approving a quarterly dividend increase from US$1.24 to US$1.25 per share.
  • An interesting angle is that Clorox expects a large portion of its projected fiscal 2027 sales growth to come from the GOJO acquisition, even as it continues to contend with inflation and value-focused consumers.
  • We’ll now examine how Clorox’s stronger-than-expected earnings and GOJO-fueled 2027 outlook may influence its existing investment narrative.

AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Clorox Investment Narrative Recap

To own Clorox, you have to believe its core brands and new health and hygiene platform can support steady earnings and cash generation, even with sluggish category growth and value-focused consumers. Right now, the key near term catalyst is management’s push to rebuild margins and share while integrating GOJO, and the biggest risk is that inflation and intense price competition in areas like Glad and cat litter keep squeezing those margins. The latest results and guidance do not remove that risk, but they do help frame it more clearly.

The fiscal 2027 outlook, calling for 13% to 14% higher net sales with about 9.5 points coming from the GOJO acquisition and a 12% to 19% increase in diluted EPS to US$5.41 to US$5.71, is the announcement that matters most here. It directly links the main short term catalyst, GOJO integration plus ERP and productivity benefits, with the main margin and demand risks, giving investors a clearer yardstick to watch as Clorox balances pricing, promotions, and cost pressures.

Yet even with GOJO, investors should be aware that persistent inflation and consumer trade down could still...

Read the full narrative on Clorox (it's free!)

Clorox's narrative projects $7.9 billion revenue and $886.0 million earnings by 2029. This requires 5.5% yearly revenue growth and about a $130 million earnings increase from $756.0 million today.

Uncover how Clorox's forecasts yield a $105.29 fair value, in line with its current price.

Exploring Other Perspectives

CLX 1-Year Stock Price Chart
CLX 1-Year Stock Price Chart

Before this earnings release, the most optimistic analysts were assuming Clorox could reach about US$8.1 billion in revenue and nearly US$1.0 billion in earnings by 2029, which is much more upbeat than consensus and leans heavily on faster ERP driven margin gains and GOJO style growth. This news could either support that story or force a rethink, so it is worth comparing those bullish expectations with your own view of how much pressure inflation and consumer trade down might still create.

Explore 6 other fair value estimates on Clorox - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

  • The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
  • We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
  • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.